Equities Analysts Set Expectations for CLDX Q1 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research note issued to investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($1.27) per share for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q2 2026 earnings at ($1.30) EPS and FY2027 earnings at ($5.53) EPS.

A number of other research analysts have also issued reports on CLDX. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday. Finally, Barclays boosted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.20.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $30.09 on Friday. Celldex Therapeutics has a one year low of $14.40 and a one year high of $31.31. The company has a 50-day simple moving average of $25.70 and a 200-day simple moving average of $25.50. The firm has a market capitalization of $2.00 billion, a P/E ratio of -7.74 and a beta of 1.24.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative return on equity of 39.67% and a negative net margin of 3,446.88%.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in shares of Celldex Therapeutics by 39.3% during the 4th quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after purchasing an additional 2,279,605 shares in the last quarter. Vanguard Group Inc. lifted its stake in Celldex Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock valued at $109,384,000 after purchasing an additional 72,817 shares during the last quarter. Bellevue Group AG lifted its stake in Celldex Therapeutics by 7.6% during the third quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock valued at $92,037,000 after purchasing an additional 250,100 shares during the last quarter. Commodore Capital LP boosted its holdings in Celldex Therapeutics by 7.8% during the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after buying an additional 250,000 shares in the last quarter. Finally, State Street Corp grew its position in Celldex Therapeutics by 19.5% in the fourth quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock worth $92,282,000 after buying an additional 555,579 shares during the last quarter.

Celldex Therapeutics News Roundup

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: New Phase 2 clinical data for barzolvolimab presented at AAAAI show sustained off‑treatment efficacy in chronic spontaneous urticaria (CSU) and meaningful quality‑of‑life gains in cold urticaria/symptomatic dermographism — potential upside for future regulatory/label discussions and commercial prospects. Celldex Presents Additional Positive Data
• Positive Sentiment: Analyst bullishness: Stifel reaffirmed a Buy and raised its price target to $68, and Morgan Stanley reiterated a Buy — these upgrades/support increase the stock’s upside narrative for investors focused on clinical catalysts. Stifel Reaffirms Buy, Raises PT
• Positive Sentiment: Sell‑side coverage remains constructive overall (average rating around “Moderate Buy”), which can sustain interest into upcoming 2026 data readouts and EMBARQ enrollment updates. TipRanks / Analyst Note
• Neutral Sentiment: HC Wainwright published EPS forecasts for FY2026/FY2027 (negative EPS expected), providing modeling detail but no change in clinical outlook; useful for valuation but not an immediate catalyst. HC Wainwright Estimates (MarketBeat)
• Neutral Sentiment: Mixed media and analyst commentary (Beaumont Enterprise, AmericanBankingNews) reinforce analyst interest but do not add new clinical or financial surprises. Q4 Snapshot
• Negative Sentiment: Recent Q4 2025 financials disappointed: the company missed EPS and revenue expectations, reported very large negative margins and negative ROE, and consensus still expects meaningful losses for 2026 — headwinds for near‑term sentiment and valuation. Q4 and Year‑End 2025 Results
• Negative Sentiment: Short interest data posted recently are inconsistent/odd (reported as zero), which may create temporary noise but reflects no clear short‑pressure signal.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.